- Home
- ROIV vs HALO Comparison
ROIV vs HALO Comparison
Compare ROIV & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | HALO |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 7.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | HALO |
|---|---|---|
| Price | $22.13 | $62.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $21.94 | ★ $73.33 |
| AVG Volume (30 Days) | ★ 6.7M | 2.5M |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | N/A | ★ 4.74 |
| Revenue | $20,329,000.00 | ★ $1,242,852,000.00 |
| Revenue This Year | N/A | $34.83 |
| Revenue Next Year | $376.94 | $24.84 |
| P/E Ratio | ★ N/A | $13.14 |
| Revenue Growth | N/A | ★ 31.19 |
| 52 Week Low | $8.73 | $46.26 |
| 52 Week High | $22.45 | $79.50 |
Technical Indicators
Market Signals| Indicator | ROIV | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 68.21 | 34.09 |
| Support Level | $20.14 | $61.23 |
| Resistance Level | $21.48 | $63.26 |
| Average True Range (ATR) | 0.66 | 2.42 |
| MACD | -0.02 | -0.79 |
| Stochastic Oscillator | 87.12 | 7.60 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.